This study focuses on patients with Multiple Myeloma, a type of blood cancer affecting plasma cells in the bone marrow. The research evaluates a combination treatment using three medications: Iberdomide, Ixazomib, and Dexamethasone. These medications are taken orally in the form of tablets or capsules. The study specifically looks at elderly patients whose disease has returned after their first treatment.
The treatment combines different doses of Iberdomide (ranging from 0.75 mg to 1.6 mg daily), Ixazomib (up to 3 mg daily), and Dexamethasone (up to 20 mg daily). The purpose of this research is to determine how well patients respond to this combination of medications, particularly in achieving a very good partial response or better to the treatment.
The study will monitor how the medications work together, how well patients tolerate them, and track any side effects that may occur. Patients will be followed for several years to assess both the short-term and long-term effects of the treatment. The study will also look at how long the treatment remains effective and how it affects patients’ quality of life.



France